Introduction: Breast cancer remains a global health problem with an increasing incidence. Breast carcinogenesis emerges by a multistep process via steps of hyperplasia, premalignant change, and in situ carcinoma. Women with proliferative breast disease have been observed to have an increased risk of breast cancer. Improved knowledge of breast carcinogenesis will provide insight for defining the high-risk groups, thus resulting in improved screening and management regimens. Materials and methods: The present study included 60 radical mastectomies for carcinoma of breast at RajaRajeswari Medical College and Hospital, Bengaluru, from August 2015 to July 2018. The primary tumor and peritumoral area were studied both grossly and microscopically for the different lesions and the results were analyzed. Observation and results: Of the 60 cases of breast carcinomas, the predominant type of carcinoma was infiltrating ductal carcinoma, no specific type (88%) (IDC, NOS). The lesions in peritumoral area were fibrocystic changes (62%), proliferative breast lesions (13%), and ductal carcinoma in situ (DCIS) (25%). Conclusion: Most of the peritumoral area showed fibrocystic changes which have a less absolute risk of 3%, whereas DCIS has an absolute lifetime risk of 25–30% transforming into carcinoma of breast, making those patients mandatory for follow-up and management.
Lap P, Tan KL, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123(4):541–546. DOI: 10.1309/YMJ3A83TB39MRUT9.
Rosen J. Chapter 10. Precancerous Breast Disease: Epidemiological, Pathological and Clinical consideration. Rosen's Breast Pathology Rosen PP, ed. 3rd ed. Lippincott Williams and Wilkins; 2009. pp. 264–284.
Schnitt SJ. Benign breast disease and breast cancer risk: morphology and beyond. Am J Surg Pathol 2003;27(6):836–841. DOI: 10.1097/00000478-200306000-00017.
Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71(4):1258–1265. DOI: 10.1002/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I.
London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267(7): 941–944. DOI: 10.1001/jama.1992.03480070057030.
Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312(3):146–151. DOI: 10.1056/NEJM198501173120303.
Palli D, Rosselli del Turco M, Simoncini R, et al. Benign breast disease and breast cancer: a case-control study in a cohort in Italy. Int J Cancer 1991;47(5):703–706. DOI: 10.1002/ijc.2910470513.
Shashikala R, Ravindra S. Proliferative fibrocystic lesions in association with carcinoma breast- Study of mastectomy specimens. Int J Biomed Adv Res 2015;6(8):574–579. DOI: 10.7439/ijbr.v6i8.2304.
Rema Nair S, Himaja S, Bhagyalakshmi A. Prospective study of histological proliferative changes in adjacent areas of breast cancer. J Evid Based Med Healthc 2016;3(90):4881–4885.
Hartmann CL, Sellers AT, Frost HM, et al. Benign Breast Disease and the Risk of Breast Cancer. N Engl J Med 2005;353(3):229–237. DOI: 10.1056/NEJMoa044383.
Wang J, Costantino JP, Tan-Chiu E, et al. Lower category benign breast disease and the risk of invasive breast cancer. J Natl Cancer Inst 2004;96(8):616–620. DOI: 10.1093/jnci/djhs105.
Ottesen GL. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. APIMS Suppl 2003(108):1–67.